دورية أكاديمية
أعرض في EDS

Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials.

التفاصيل البيبلوغرافية
العنوان: Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials.
المؤلفون: Rivera FB; Department of Medicine, Lincoln Medical Center, New York, NY, USA., Cruz LLA; University of the Philippines College of Medicine, Manila, Philippines., Magalong JV; University of the Philippines College of Medicine, Manila, Philippines., Ruyeras JMMJ; Cebu Institute of Medicine, Cebu, Philippines., Aparece JP; Department of Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA., Bantayan NRB; University of the Philippines College of Medicine, Manila, Philippines., Lara-Breitinger K; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, (MN), USA., Gulati M; Department of Cardiology, Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, USA.
المصدر: American journal of preventive cardiology [Am J Prev Cardiol] 2024 May 07; Vol. 18, pp. 100679. Date of Electronic Publication: 2024 May 07 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101769122 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-6677 (Electronic) Linking ISSN: 26666677 NLM ISO Abbreviation: Am J Prev Cardiol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B.V., [2020]-
مستخلص: Background: Multiple cardiovascular outcomes trials (CVOTs) have shown the efficacy of GLP-1RAs in reducing major adverse cardiovascular events (MACEs) for high-risk patients. However, some CVOTs failed to demonstrate cardiovascular benefits.
Objectives: We analyzed the impact of GLP-1RA on cardiovascular and renal outcomes in patients with or without T2DM, with subgroup analysis based on sex, estimated glomerular filtration rate (eGFR), body mass index (BMI), and history of cardiovascular disease (CVD).
Methods: A comprehensive database search for placebo-controlled RCTs on GLP-1RA treatment was conducted until April 2024. Data extraction and quality assessment were carried out, employing a robust statistical analysis using a random effects model to determine outcomes with log odds ratios and 95 % confidence intervals (CIs).
Results: A total of 13 CVOTs comprising 83,258 patients were included. GLP-1RAs significantly reduced MACE (OR 0.86, 95 % CI: 0.80 to 0.94, p < 0.01) all-cause mortality OR 0.87, 95 % CI: 0.82 to 0.93, p < 0.001, CV mortality (OR 0.87, 95 % CI: 0.81 to 0.94, p < 0.001), stroke (fatal: OR 0.74, 95 % CI: 0.56 to 0.96, p = 0.03; non-fatal: OR 0.87, 95 % CI: 0.79 to 0.96, p = 0.005), coronary revascularization (OR 0.86, 95 % CI: 0.74 to 0.99, p = 0.023), and composite kidney outcome (OR 0.76, 95 % CI: 0.67 to 0.85, p < 0.001. GLP-1RA significantly reduced MACE in both sexes. Furthermore, GLP-1RA reduced MACE regardless of CVD history, BMI, and eGFR level.
Conclusion: Significant reductions in MACE, overall and CV mortality, stroke, coronary revascularization, and composite kidney outcome with GLP-1RA treatment were noted across all subgroups.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2024 The Author(s).)
References: Eur Heart J. 2021 Sep 7;42(34):3227-3337. (PMID: 34458905)
Eur Heart J. 2023 Oct 14;44(39):4043-4140. (PMID: 37622663)
BMJ. 2009 Jul 21;339:b2700. (PMID: 19622552)
Front Endocrinol (Lausanne). 2022 Dec 05;13:1007980. (PMID: 36545339)
J Clin Epidemiol. 2018 Aug;100:103-110. (PMID: 29339215)
N Engl J Med. 2019 Aug 29;381(9):841-851. (PMID: 31185157)
Curr Opin Pharmacol. 2021 Oct;60:40-45. (PMID: 34325380)
Front Neuroendocrinol. 2017 Jul;46:46-70. (PMID: 28428055)
N Engl J Med. 2017 Aug 31;377(9):839-848. (PMID: 28854085)
Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785. (PMID: 31422062)
Lancet. 2019 Jul 13;394(10193):121-130. (PMID: 31189511)
N Engl J Med. 2016 Jul 28;375(4):311-22. (PMID: 27295427)
N Engl J Med. 2017 Sep 28;377(13):1228-1239. (PMID: 28910237)
N Engl J Med. 2021 Sep 2;385(10):896-907. (PMID: 34215025)
N Engl J Med. 2023 Sep 21;389(12):1069-1084. (PMID: 37622681)
Diabetes Obes Metab. 2024 Jun;26(6):2209-2228. (PMID: 38505997)
Nat Med. 2022 Jan;28(1):89-95. (PMID: 34873344)
Circulation. 2019 Apr 23;139(17):2022-2031. (PMID: 30786725)
Lancet. 2018 Oct 27;392(10157):1519-1529. (PMID: 30291013)
Am Heart J Plus. 2023 Feb;26:. (PMID: 37305172)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
Metabolites. 2022 Feb 15;12(2):. (PMID: 35208256)
N Engl J Med. 2016 Nov 10;375(19):1834-1844. (PMID: 27633186)
N Engl J Med. 2023 Dec 14;389(24):2221-2232. (PMID: 37952131)
J Clin Epidemiol. 2023 Jul;159:40-48. (PMID: 37146659)
JAMA. 2016 Aug 2;316(5):500-8. (PMID: 27483064)
Cardiovasc Diabetol. 2021 Sep 15;20(1):189. (PMID: 34526024)
J Am Coll Cardiol. 2020 Mar 17;75(10):1128-1141. (PMID: 32164886)
Diabetologia. 2021 Dec;64(12):2676-2686. (PMID: 34536085)
Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113. (PMID: 29221659)
Eur Heart J. 2021 Sep 21;42(36):3599-3726. (PMID: 34447992)
Eur Heart J. 2020 Jan 14;41(3):407-477. (PMID: 31504439)
Mol Metab. 2019 Dec;30:72-130. (PMID: 31767182)
BMJ. 2021 Jan 13;372:m4573. (PMID: 33441402)
Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(9):631-641. (PMID: 37608465)
Eur Heart J. 2023 Oct 12;44(38):3720-3826. (PMID: 37622654)
N Engl J Med. 2015 Dec 3;373(23):2247-57. (PMID: 26630143)
N Engl J Med. 2024 Apr 18;390(15):1394-1407. (PMID: 38587233)
Circulation. 2023 Aug 29;148(9):e9-e119. (PMID: 37471501)
Lancet Reg Health West Pac. 2023 Jan 31;33:100692. (PMID: 37181530)
Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-662. (PMID: 34425083)
Cardiovasc Diabetol. 2020 Sep 29;19(1):154. (PMID: 32993654)
فهرسة مساهمة: Keywords: Cardiovascular outcomes; GLP-1RA; Glucagon-like peptide 1 receptor agonists; MACE; Renal outcomes
تواريخ الأحداث: Date Created: 20240523 Latest Revision: 20240524
رمز التحديث: 20240524
مُعرف محوري في PubMed: PMC11108827
DOI: 10.1016/j.ajpc.2024.100679
PMID: 38779187
قاعدة البيانات: MEDLINE
الوصف
تدمد:2666-6677
DOI:10.1016/j.ajpc.2024.100679